期刊
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
卷 34, 期 3, 页码 355-361出版社
WILEY
DOI: 10.1111/j.1365-2710.2009.01046.x
关键词
C-reactive protein; gamma-glutamylhydrolase; methotrexate; polymorphism; reduced folate carrier; rheumatoid arthritis
资金
- University of Shizuoka
Low-dose methotrexate (MTX) therapy is widely used in the treatment of rheumatoid arthritis (RA). Though the difference in response to MTX between patients with RA is large, the factors that contribute to this variability remain unclear. We aimed to identify those factors with a particular emphasis on the pharmacogenetics of MTX. We evaluated the association of possible factors, including genetic polymorphisms of folate metabolic pathway enzymes, with the cumulative value of C-reactive protein, an index of MTX anti-inflammatory efficacy, in 87 Japanese patients with RA. Polymorphisms of the reduced folate carrier gene (RFC) G80A and of the gamma-glutamylhydrolase gene (GGH) C-401T were more closely associated (beta = 2.1194, P = 0.0017) than other polymorphisms, with the anti-inflammatory response to MTX. Patients with RA having RFC 80A and GGH-401T alleles were less responsive to MTX than those with RFC 80A and without GGH-401T alleles. Thus, this data may be useful for guiding treatment of RA patients with MTX.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据